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Background: Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver oncogene, BCR-
ABL1, which is a constitutive tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the central treatment strategy for CML
patients and have signiﬁcantly improved survival rates, but the T315I mutation in the kinase domain of BCR-ABL1 confers
resistance to all clinically approved TKIs, except ponatinib. However, compound mutations can mediate resistance even
to ponatinib and remain a clinical challenge in CML therapy. Here, we investigated a ponatinib-resistant CML patient
through whole-genome sequencing (WGS) to identify the cause of resistance and to ﬁnd alternative therapeutic targets.
Patients and methods:We carried out WGS on a ponatinib-resistant CML patient and demonstrated an effective com-
bination therapy against the primary CML cells derived from this patient in vitro.
Results: Our ﬁndings demonstrate the emergence of compound mutations in the BCR-ABL1 kinase domain following
ponatinib treatment, and chromosomal structural variation data predicted ampliﬁcation of BCL2. The primary CD34+
CML cells from this patient showed increased sensitivity to the combination of ponatinib and ABT-263, a BCL2 inhibitor
with a negligible effect against the normal CD34+ cells.
Conclusion: Our results show the potential of personalised medicine approaches in TKI-resistant CML patients and
provide a strategy that could improve clinical outcomes for these patients.
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introduction
Chronic myeloid leukaemia (CML) is driven by a constitutive
tyrosine kinase, BCR-ABL1, which results from a reciprocal
translocation t(9;22)(q34;q11) in haemopoietic stem cells [1].
Tyrosine kinase inhibitors (TKIs) are the main treatment of
CML and have improved disease management and survival [2].
However, resistance is a persistent clinical problem and a signiﬁ-
cant proportion of patients will progress on ﬁrst-line therapy
due to the emergence of TKI-resistant clones. In some patients,
TKI resistance is mediated by BCR-ABL1-independent mechan-
isms, including increased BCL2 expression and overexpression
of LYN kinase, but 20%–30% of patients progress due to
acquired point mutations in the BCR-ABL1 kinase domain that
disrupt TKI binding. In particular, BCR-ABL1 p.T315I (the
‘gatekeeper’ mutation) confers resistance to all approved ﬁrst-
and second-line TKIs, including imatinib, nilotinib, dasatinib,
and bosutinib [3–5].
Notably, BCR-ABL1 p.T315I remains sensitive to the TKI
ponatinib, a third-line inhibitor [6]. Although an initial
response to ponatinib is promising in patients with single
mutations in BCR-ABL1, response in advanced patients is
limited because successive or long-term use of TKIs lead to the
evolution of compound BCR-ABL1 kinase domain mutations
that show resistance even to ponatinib [7, 8]. No fourth-line
treatments have yet been approved for ponatinib-resistant
CML.
We used whole-genome sequencing (WGS) to characterise a
ponatinib-resistant CML patient. This revealed a constellation
of BCR-ABL1 mutations that were not detected in diagnostic
Sanger sequencing approaches. The WGS approach also re-
vealed ampliﬁcation of the anti-apoptotic gene BCL2 and we
show that this patient’s CML cells were susceptible to a ponati-
nib/ABT-263 combination, revealing a therapeutic strategy that
may have been effective in this patient.
patients andmethods
Detailed experimental procedures are in supplementary Methods, available
at Annals of Oncology online. Brieﬂy, tissues were collected following
informed consent and ethical approval from the scientiﬁc subcommittee of
the Manchester Cancer Research Centre Tissue Biobank and in compliance
with the ethical and legal framework of the Human Tissue Act, 2004.
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Normal mobilised CD34+ cells surplus to requirements were from patients
undergoing chemotherapy and autologous transplantation for myeloma.
Their use was authorised by the Salford and Trafford Research Ethics
Committee, for samples collected since 2006, and following written
informed consent of donors. Isolated CML CD34+ cells were expanded
ex vivo for genomic DNA extraction. Germline DNA was extracted from the
buccal epithelial cells from the patient’s fresh saliva. Total RNA from CML
CD34+ cells was used for RNA-seq and shot-gun cloning. WGS and RNA-
seq were carried out on an Illumina HiSeq2500 in paired-end 100-bp runs,
with 65× depth for CML DNA and 35× depth for germline DNA. Raw data
are accessible via EGAS00001001150. Detailed computational methods are
in supplementary Methods, available at Annals of Oncology online.
Validation and identiﬁcation of single and compound mutations in the
BCR-ABL1 kinase domain was by shot-gun cloning and Sanger sequencing
[9]. Annexin V apoptosis assays (BD Biosciences) and cell proliferation
assays (CellTiter 96 Aqueous One Solution; Promega) were as per manu-
facturers’ instructions. Colony forming cell (CFC) assays were used to
examine CML CD34+ cell differentiation following small molecule inhibitor
treatments.
results
We report on a patient in their 70s who presented with chronic
phase CML. The patient was initially treated with imatinib (400
mg/day), which resulted in a complete haematological response
(CHR), but failed to achieve a complete cytogenetic response
(CCR) at 6 months (Figure 1 A). Dose escalation of imatinib
(600 mg/day), followed by the second-generation TKI dasatinib
(100 mg/day), each for 6 months also failed to produce a CCR
(Figure 1A) and due to nilotinib and interferon intolerance, the
patient was again placed on standard-dose imatinib. BCR-ABL1
mutation analysis at this time demonstrated a C>T, p.T315I mu-
tation, but the patient was not considered suitable for allogeneic
bone marrow transplantation due to co-morbidities. In the
absence of haematological response, imatinib was discontinued and
the patient was treated with hydroxycarbamide. Three years follow-
ing diagnosis, the patient was treated with ponatinib (45 mg/day)
and despite achieving a temporary CHR, a CCR was never
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Figure 1. Timeline of CML patient’s treatments and the study design. (A) TKI and non-TKI treatments shown as coloured boxes over the horizontal timeline
axis. The time point of blood sample collection for the WGS study is indicated (red triangle). Inset shows the BCR-ABL1 FISH results for this blood sample. (B)
Schematic diagram showing the extraction of tumour genomic DNA (gDNA) from CD34+-enriched peripheral blood mononucleated cells (MNCs) that are
expanded in a colony forming cell (CFC) assay, and the extraction of germline gDNA from buccal epithelial cells using FACS, for WGS. CML, chronic myeloid
leukaemia; TKIs, tyrosine kinase inhibitors.
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achieved, and within 9 months the CHR was lost, as revealed by a
rising white blood cell count. The patient was retreated with
hydroxycarbamide, but developed leg ulceration necessitating dis-
continuation (Figure 1A). The patient remains in chronic phase
with disease control being achieved with intermittent etoposide
(Bristol-Myers Squibb Pharmaceuticals Limited, Uxbridge).
To characterise further the patient’s disease, we carried out
WGS on CD34+ cells isolated from blood 57 months after diag-
nosis (Figure 1A and B). The CD34+ cells were 99.5% BCR-
ABL1+ by FISH, and germline DNA was isolated from buccal
epithelial cells (Figure 1A and B). We observed 12 466 predicted
somatic single-nucleotide variants (SNVs) in the patient’s CML
cells, resulting in 23 predicted non-synonymous mutations
(Table 1), a modest mutational burden that is similar to that
seen in acute myeloid leukaemia (AML), but considerably lower
than that in cutaneous melanoma, colorectal adenocarcinoma,
and lung cancers, which are associated with known carcinogens
(Figure 2A). Approximately 40% of the somatic mutations were
C>T (G>A) transitions and approximately 20% T>C (A>G)
transitions (Figure 2B), also a common mutation signature in
AML [10]. Trinucleotide analysis of the mutant base and its ﬂank-
ing nucleotides (Figure 2C) revealed a match to the recently
described mutational signature 1B, which is common in several
cancers including AML, acute lymphoblastic leukaemia (ALL),
chronic lymphocytic leukaemia (CLL), and B-cell lymphoma [11].
Among the 23 predicted somatic coding region SNVs, 10
occur at a frequency of <0.05% in the dbSNP database (Table 1
and Figure 3A). Notably, RNA-seq analysis revealed that only
12 of the 23 predicted SNVs were expressed and of the 4 previ-
ously reported in cancers (COSMIC, http://cancer.sanger.ac.uk/
cosmic), only ABL1 (C>T, p.T315I) and ABL1 (T>G, p.F359V)
were expressed (Table 1). The ABL1 mutations are also the only
missense SNVs that have been reported in CML (COSMIC) and
have a damaging effect on protein function as predicted by SIFT
and PolyPhen scores (Table 1). We used a 10% threshold to call
the SNVs (supplementary Methods, available at Annals of
Oncology online), so to detect lower-frequency SNVs in the
ABL1 kinase domain we set the detection limit to 0.1%, but did
not detect any additional mutations. However, when we manu-
ally scanned this region in the Integrative Genomic Viewer
(IGV v2.3.3.38), we observed an additional 53 low-frequency
SNVs, but only 2 of these were validated by Sanger sequencing
(supplementary Table S1, available at Annals of Oncology online).
To investigate this region further, we carried out PCR-mediated
shot-gun cloning and Sanger sequencing of the BCR-ABL1 kinase
domain [12], comparing a pre-ponatinib sample from 21 months
to the post-ponatinib sample obtained at 57 months. The p.T315I
mutation was present in 100% of the clones from the pre-ponati-
nib sample and ∼21% of these carried additional point mutations
(Figure 3B), including p.E225G/T315I and p.T315I/F359C
compound mutations (supplementary Table S2, available at
Annals of Oncology online), which have been shown to mediate
ponatinib resistance [8]. Intriguingly, following ponatinib treat-
ment, we observed a reduction of p.T315I to ∼17% of the clones,
with emergence of a new dominant clone (∼53%) carrying a p.
F359V mutation (Figure 3B). Moreover, following ponatinib, the
number of compound mutations increased to ∼45% and included
p.T315I/M351V which also confers ponatinib resistance [8] (sup-
plementary Table S2, available at Annals of Oncology online).
We predicted 58 loss of heterozygosity (LOH) SNVs in the
coding regions, 20 of which have been reported (COSMIC;
Figure 3A and supplementary Table S3, available at Annals of
Oncology online). We predicted 183 somatic small insertions or
deletions (indels), but none in the coding regions. We also pre-
dicted 12 chromosomal translocations with the potential to gen-
erate fusion genes, 2 of which were the balanced t(9;22)(q34;
q11) reciprocal translocations that create BCR-ABL1 (Figure 3A
and supplementary Table S4, available at Annals of Oncology
online). However, our RNA-seq revealed that only BCR-ABL1
and ABL1-BCR were expressed, strongly suggesting that BCR-
ABL1 was the driver oncogene (supplementary Table S4, avail-
able at Annals of Oncology online) and that the other potential
fusions were not pathogenic.
We predicted 53 large chromosomal deletions and 7 large
chromosomal ampliﬁcations (Figure 3A). Two of the deletions
and three of the ampliﬁcations affected coding regions (supple-
mentary Table S5, available at Annals of Oncology online).
A large deletion of 5q23 is similar to that previously described in
a blast crisis patient (supplementary Table S5, available at Annals
of Oncology online), but we noted an ∼8 Mb ampliﬁcation of
chromosome 18q that harbours the anti-apoptotic gene BCL2.
BCL2 upregulation is associated with sensitivity to BCL2 inhibi-
tors, so we modelled this using two BCR-ABL1+ cell lines, BV173R
and K562 cells. BV173R cells expressed approximately seven-fold
more BCL2 than K562 cells (Figure 4A) and were signiﬁcantly
more sensitive to a BH3-mimetic BCL2 inhibitor, ABT-263 [13]
(Figure 4B). We conﬁrmed that BCL2 expression was 14-fold
higher in the patient’s CD34+ CML cells than normal mobilised
CD34+ cells (Figure 4A), and that the patient’s CD34+ cells were
more sensitive to ABT-263 (Figure 4B). Moreover, ponatinib and
ABT-263 cooperated to increase apoptosis in the patient’s CD34+
cells (Figure 4C). These results were reﬂected in viability assays.
Ponatinib and ABT-263 did not signiﬁcantly suppress the viability
of normal CD34+ cells (Figure 4D), but both inhibited growth of
the patient’s CD34+ cells and they cooperated to suppress the
growth of these cells (Figure 4E). We also examined ABT-199, a
second BCL2 inhibitor [14]. ABT-199 was less potent than ABT-
263 at inducing apoptosis in the patient’s CD34+ cells (supple-
mentary Figure S1A, available at Annals of Oncology online), but it
nevertheless cooperated with ponatinib to enhance apoptosis (sup-
plementary Figure S1B, available at Annals of Oncology online).
Next, we examined the differentiation capacity of the patient’s
CD34+ cells that survived the drug treatments. In CFC assays, only
∼5% of the control colonies were erythroid and ∼95% were gran-
ulocytic, but the granulocytic fraction decreased to ∼85% in the
presence of ponatinib, to ∼60% in the presence of ABT-263, and
to only 24% in the presence of both drugs, a trend that was also
observed with ABT-199 (Figure 4F and G; supplementary Figures
S1C and S2, available at Annals of Oncology online). Thus, in add-
ition to inducing apoptosis and reducing viability, the ponatinib/
ABT-263 combination selectively reduced production of granulo-
cytic lineage cells, either by inducing lineage-speciﬁc apoptosis or
differentiation of surviving cells down the erythroid lineage.
discussion
We report WGS analysis of a CML patient and observe a muta-
tion signature predominated by C>T transitions and a
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Table 1. List of the genes with missense somatic SNVs in CML cells.
Gene Genomic
varianta
Protein variant SIFT PolyPhen COSMIC dbSNP (%MAF) CML DNA (%MAF) Normal DNA CML RNA #1
(%MAF)
CML RNA #2
(%MAF)
ABL1 chr9:133748283C > T T315I 0 1 COSM12560,
COSM12603
rs121913459 (N/A) 11/65 (16.92%) 0/37 11/145 (7.59%) 21/142 (14.79%)
ABL1 chr9:133748414T > G F359V 0 0.999 COSM12605,
COSM133668
rs121913452 (N/A) 21/70 (30%) 1/28 29/150 (19.33%) 29/173 (16.67%)
C1orf168 chr1:57233559A > G Y336H 0.02 0.931 24/63 (38.09%) 2/41 0 0
CANT1 chr17:76993184T > C N174S 0.08 0.326 40/71 (40.84%) 0/36 91/184 (49.46%) 86/190 (45.26%)
CNTNAP3 chr9:39132947G > A R688W 0 0.934 29/54 (53.7%) 0/23 0 0
DPY19L2 chr12:63964599T > C I647V 1 0.006 COSM1128502 7/53 (13.2%) 1/33 0 0
GTSE1 chr22:46724662C > T P601L 0 0.139 45/80 (56.25%) 0/35 131/248 (52.82%) 117/226 (51.77%)
IGFN1 chr1:201178965A > G I1648M 0.05 0.007 rs12758143 (N/A) 9/47 (19.14%) 0/25 0 0
ITIH1 chr3:52821993T > C L5P 0.11 0 rs71299618 (N/A) 6/34 (17.64%) 0/15 0 0
KIAA1522 chr1:33207790G > A G79S 0.07 0 36/72 (50%) 0/14 0 0
LARS chr5:145499963C > T R1072H 0.04 0.978 rs145644461 (0.05%) 15/79 (18.98%) 0/44 77/551 (13.97%) 70/614 (11.38%)
MARCH9 chr12:58152559C > T T307M 0 0.026 rs370203524 (0.01%) 45/85 (52.94%) 0/32 19/47 (40.43%) 17/28 (60.71%)
MT-ND1 chrM:3448A > C Q47H 0 0.991 1326/9888 (13.41%) 747/5180 0 0
NBPF1 chr1:16891365G > A T1038M 0.1 0.01 rs201912185 (N/A) 73/607 (12.02%) 17/280 6/43 (13.64%) 8/31 (25.81%)
NBPF10 chr1:145323656A > T I1165F 0.19 0.493 COSM895149 rs75252120 (N/A) 58/420 (13.8%) 21/207 0 0
NCKAP5 chr2:133542514C > T G624R 0.43 0.066 34/65 (52.3%) 1/29 0 0
SCG2 chr2:224462853C > T R383Q 0.9 0.001 rs139176325 (0.04%) 12/65 (18.46%) 2/41 0 0
SMPD2 chr6:109763241A > G I97V 0.18 0 48/75 (50.66%) 0/30 42/75 (56%) 47/88 (53.41%)
SNRPA1 chr15:101825161C > T M135I 0.22 0 31/80 (38.75%) 0/31 0 4/13 (30.77%)
UACA chr15:70980121C > A D142Y 0 1 37/87 (42.52%) 0/36 4/12 (33.33%) 4/11 (36.36%)
XIRP1 chr3:39230480C > T V153I 0 0.996 rs201031340 (0.05%) 28/64 (43.75%) 0/29 0 0
ZBTB46 chr20:62407126C > T S376N 0.41 0.597 49/90 (54.44%) 0/19 5/12 (41.67%) 0
ZZEF1 chr17:3999258T > C I594V 0.17 0.995 32/64 (50%) 1/36 38/97 (39.18%) 41/88 (46.07%)
Colour coding: red cells, missense mutations with damaging effect on protein function; green cells, tolerated missense variants.
a hg19 genomic coordinates.
% MAF, percentage of mutant allele frequency.
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trinucleotide signature 1B. These mutations are thought to
result from spontaneous deamination of 5-methyl-cytosine in
germline and normal somatic cells [11]. Although the aetiology
of these cells is unclear, this signature is age-related and particu-
larly common in haematological malignancies including ALL,
AML, CLL, and B-cell lymphoma [11], suggesting a common
somatic mutation mechanism in these diseases.
We observed a modest mutational burden, characteristic of
cancers that are not associated with known carcinogens such as
ultraviolet light or cigarette smoke. Moreover, the WGS revealed
an ABL1 p.F359V mutation that was not detected by diagnostic
Sanger sequencing. We conﬁrmed the presence of this mutation
by shot-gun cloning and Sanger sequencing, and it is unclear
why the diagnostic Sanger sequencing did not reveal this muta-
tion, but one possibility is that the wild-type codon is favoured
for base incorporation and thereby masks the mutant allele. The
shot-gun sequencing also revealed several compound mutations
that were not identiﬁed by WGS, because read-length limita-
tions only reveals these when they are within ∼100 bases of each
other. Finally, the shot-gun sequencing identiﬁed many low-
frequency BCR-ABL1 kinase domain mutations that were not
revealed by WGS, possibly because of low read-depth in our
WGS or because they are PCR-generated artefacts of the shot-
gun cloning. These observations highlight why a combination of
sequencing approaches is desirable when performing these
studies, but these considerations aside, our data suggest that
there was dramatic treatment-driven clonal evolution. This pre-
sumably accounts for the failure to achieve a CCR despite the
initial haematological response and is in agreement with recent
data, showing that p.T315I TKI-resistant CML patients fail to
respond to ponatinib due to emergence of compound BCR-
ABL1 kinase domain mutations [8]. It has also been reported
that sequential TKI treatments in relapsed CML patients can
drive clonal selection of BCR-ABL1 mutants that were present at
a low frequency before treatment commenced [12, 15].
The reciprocal t(9;22)(q34;q11) translocation is the hallmark
of CML [1]. It was predicted by our WGS and RNA-seq results,
and validated by our shot-gun cloning approach. The BCR-
ABL1 fusion gene in this patient is the e14a2 isoform that
occurs between exons 14 and 15 of BCR, generating the BCR-
ABL1 p210 fusion protein. The importance of e13a2 and e14a2
isoforms to risk stratiﬁcation at the time of diagnosis is debated,
but it has been suggested that the e14a2-type CML cells can acti-
vate HLA-mediated T-cell response that can be exploited in
IFN-α therapy [16].
It is unclear what contribution the large chromosomal struc-
tural variations (SVs) made towards the disease. A putative
ampliﬁcation of ∼42 Mb on chromosome 6 harbours 370 genes,
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Figure 2. Mutational signature and mutational burden of CML. (A) Average number of non-synonymous SNVs found in different cancers (The Cancer
Genome Atlas, www.cbioportal.org) compared with the CML patient. CCRCC, clear cell renal cell carcinoma; SNVs, single-nucleotide variants. (B) Mutational
signature of the predicted 12 466 SNVs in both strands. (C) Trinucleotide mutational signature based on the 96 substitution classiﬁcation deﬁned by the type of
substitution and the immediate 30 and 50 bases adjacent to the mutated base. Vertical axes in (B) and (C) show the percentage of each mutation class.
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including 16 HLA family genes that modulate T-cell response
towards leukaemic cells [16]. This region also includes TNF,
which modulates CML CD34+ cell survival, and whose co-
inhibition with BCR-ABL1 induces CML cell death [17].
Importantly, we observed a putative ∼8 Mb ampliﬁcation on
chromosome 18 that harbours BCL2, a pro-survival driver onco-
gene in B-cell lymphomas [18]. BCL2 is important in CML
pathogenesis, progression to blast crisis [19, 20], and its
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Figure 3. Genomic characterisation of patient’s CML. (A) Circos plot illustrates the predicted somatic variants including gene-speciﬁc SNVs (green gene
names), genes affected by LOH (black gene names), genes affected by translocations (purple gene names), and the key genes targeted by SV ampliﬁcations (red
gene names) and SV deletions (blue gene names) predicted in CML cells compared with germline. Inter- and intrachromosomal rearrangements are shown by
purple lines. The genomic locations of LOH SNVs (black lines), ampliﬁcation (red line), and deletion (blue line) SVs are indicated. Grey lines mark the position
of centromeres in each chromosome. (B) Shot-gun cloning and sequencing of the BCR-ABL1 kinase domain in the samples obtained before and after ponatinib
treatment. Each bar represents the percentage of single or compound mutations of the total number of sequenced clones. SNVs, single-nucleotide variants;
LOH, loss of heterozygosity; SV, structural variation; CML, Chronic myeloid leukaemia.
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Figure 4. Ponatinib and ABT-263 co-operate to induce death or differentiation of CD34+ chronic myeloid leukaemia (CML) cells. (A) BCL2 mRNA levels in
the patient’s CD34+ CML cells, K562 and BV173R cells, and normal donor CD34+ cells. P-values were calculated relative to the average normal CD34+ BCL2
mRNA levels. ***P < 0.0001. (B) Normalised percentage of viable cells (Annexin V−) following 72 h treatment with DMSO (control) or ABT-263. *P < 0.05;
**P < 0.01. (C) FACS dot plots showing changes in the percentage of apoptotic cells (Annexin V+; horizontal axes) in CD34+ CML cells treated with DMSO,
ponatinib, ABT-263, and the combination for 72 h. (D) Cell proliferation assays for normal CD34+ cells, and (E) CML patient’s CD34+ cells treated with
DMSO, ponatinib, ABT-263, or the combination for 72 h. *P < 0.05; **P < 0.01; ns, not signiﬁcant. (F) Proportion of granulocytic and erythroid colonies fol-
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overexpression is associated with TKI resistance [3]. BCL2 inhi-
bitors such as ABT-263 and ABT-199 are in phase 2 clinical
trials [14, 21]. We ﬁnd that the chromosomal SV that leads to
BCL2 ampliﬁcation in this patient was associated with elevated
BCL2 expression and sensitivity to ABT-263 as has been
reported for B-cell lymphomas and ALL cells harbouring an
IGH-BCL2 fusion or trisomy 18 [13]. However, in other reports,
only a modest induction in apoptosis was seen with ABT-263
in BCR-ABL1+ CML cells without any effects on stem cell sur-
vival or self-renewal capacity [13, 22]. Using cell lines, we show
that the response to ABT-263 is correlated to high levels of
BCL2 and independent of BCR-ABL1 expression, supporting
the conclusion that the response to ABT-263 we observed in the
CML patient’s CD34+ cells is due to the BCL2 ampliﬁcation.
This observation suggests BCR-ABL-dependent and BCR-ABL-
independent mechanisms of resistance in this patient and
notably, the patient’s CML cells were highly sensitive to com-
bined inhibition of both resistance pathways. Moreover, the cells
that survived the combination treatment favoured erythroid
over granulocytic lineage differentiation.
Thus, in summary, we describe the ﬁrst WGS of CML. The
patient developed ponatinib-resistant disease and our data
suggest that the underlying mechanism was driven by com-
pound BCR-ABL1 kinase domain mutations and BCL2 overex-
pression. Our study describes an approach to personalised
medicine for CML and we provide a proof-of-principle that the
integration of WGS and functional studies can identify new
combination treatments for patients who have failed even third-
generation BCR-ABL1 inhibitors. Unfortunately, in this case, we
were unable to translate our ﬁndings into patient’s beneﬁt
because ABT-263 is not currently licensed.
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